Study #2024-0294
A Phase I, open-label, dose escalation study to investigate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of ONO-7018 in patients with relapsed or refractory Non-Hodgkin Lymphoma (NHL) or Chronic Lymphocytic Leukemia (CLL)
MD Anderson Study Status
Not Accepting
Treatment Agent
ONO-7018
Description
This is a Phase 1, open-label, multicenter study. This will be the first-in-human clinical study for ONO-7018 and will be conducted in two phases: a Dose Escalation Phase (Part 1) and a Dose Expansion Phase (Part 2).
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell
Study phase:
Phase I
Physician name:
Ranjit Nair
Department:
Lymphoma/Myeloma
For general questions about clinical trials:
1-888-448-0874
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.